Bone Abstracts

Histomorphometry is often adopted as a methodological approach in research of femoral bone structure. However, it is common do not describe technical details of procedure especially on the steps of macroscopy, paraffin embedding and microtomy. So we propose a simplified, reliable and reproducible method of histological processing for intertrochanteric region and femoral neck of mice, to ensure the achievement of tissue sections with similar structures, cell populations and his...

The Rickets is a disease which disturbs normal bone formation through different methods, like vitamin D deficiency, malabsorption, chronic renal disease, metaphisary dysplasia, low phosphorus and resistant rickets.The peak age at which rickets is most prevalent is usually 3–18 months, and the characteristic clinical features of this metabolic bone disease include enlargement of the epiphyses of the long bones and rib cage, bowing of the legs, bendin...

It is well known that thyroid hormone (TH) is essential for normal bone growth and development. However, the mechanisms by which TH regulates these processes are poorly understood. Recently, the sympathetic nervous system (SNS) was identified as a potent regulator of bone metabolism. In vivo studies by our group have shown that TH interacts with the SNS to regulate bone mass and structure, and that this interaction involves α2 adrenoceptor (α2-A...

Background: Long-term use of bisphosphonates has raised concerns about the association with Atypical Femur Fractures (AFFs) that have been reported mainly in postmenopausal women.Clinical case: An 18-year-old patient with juvenile osteoporosis based on X-linked osteoporosis due to a PLS3 mutation developed a low trauma femoral fracture after seven years of intravenous and two years of oral bisphosphonate use, fulfilling the revised ASBMR diagnostic crite...

Objectives: X-linked hypophosphataemia (XLH) is a rare, inherited, genetic disease characterised by renal phosphate wasting, bone mineralisation defects, rickets, abnormal tooth development, poor growth and, often, bone pain. Common treatment of children involves supplementation with oral phosphate and active vitamin D (often termed ‘conventional therapy’). The objective of this study was to identify and understand the perceived limitations of conventional therapy fo...

Objectives: Strong coordination between osteoblasts and bone marrow cells is fundamental for the regulation of healthy bone turnover and other (patho)physiological processes. Extracellular vesicles (EVs) mediate communication between cells via horizontal transfer of proteins and nucleic acids. Osteoblasts secrete EVs in the form of matrix vesicles involved in bone mineralization, however, information about a role in intercellular communication is still lacking. In this study, ...

The lactation has been considered a cause of bone loss in humans and animals. Studies have shown that during lactation, there is a significant reduction of bone mineral density. Rats at the end of lactation show reduced bone mass. The objective of this study was to verify the effect of lactation under osteogenic potential of bone marrow mesenchymal stem cells (BMMSCs) of female rats. Twelve Wistar rats were distributed among the control and lactating groups. The experiment was...

Objectives: Maximising peak bone mass (PBM) during growth is an essential part in the prevention of fractures and osteoporosis later in life. Two of the most important modifiable factors influencing PBM are diet and physical activity (PA). These factors can have either a direct or indirect effect on bone. For example, increasing PA would increase loads directly to the bone or cause muscle changes which would drive changes in bone. This study aimed to assess whether there was a...

Objective: This study aimed to evaluate the efficacy of the treatment with pamidronate disodium (PD) with respect to the increase of bone mineral density (BMD) in patients with osteogenesis imperfecta (OI).Patients and methods: We evaluated nine patients (six boys) with OI (four with type III, four with type IV, one with type I) treated with PD from 4.68 to 7.92 years (mean±S.D.: 6.75±1.38 years). Intravenous PD was administered ...

see PP446....